Lessons Learned from Recent Hypertension Trials about Kidney Disease

[摘要] This article reviews BP trials with primary or secondary cardiovascular (CV) or renal end points. It focuses on how results of recent trials have influenced guidelines and clinical practice with specific reference to two issues: (1) Achievement of goal BP in patients with chronic kidney disease and (2) emerging data on the importance of decreasing proteinuria to prevent CV events and slow kidney disease progression. Each study is evaluated on its strengths and weaknesses as well as extrapolation of findings to the general population. The tenants of this article are that the baseline level of proteinuria and the magnitude of proteinuria reduction are important determinants of renal outcome in addition to lowering BP and should be consider in all future trials. Second, comparing trials of people with different stages of nephropathy and unknown or differing levels of proteinuria is limited in generalizing the CV or renal outcome to a more global population.

[学科分类] 泌尿医学

[关键词] Bone marrow necrosis;Sickle cell disease;Hyperhemolysis syndrome